Baseline demographic and clinical characteristics of patients with rheumatoid arthritis who received biological therapy
| Variables | Adalimumab | Tocilizumab | p Value |
| (n=32) | (n=33) | ||
| Age (years) | 55.37±13.06 | 54.63±14.25 | 0.829 |
| Gender (female, %) | 27 (84.4) | 24 (72.7) | 0.367 |
| Body mass index (kg/m2) | 22.58±3.86 | 23.06±4.18 | 0.631 |
| Baseline DAS28 score | 6.59±0.44 | 6.34±0.64 | 0.43 |
| Diabetes | 3 (9.4) | 6 (18.2) | 0.475 |
| Hypertension | 8 (25.0) | 15 (45.5) | 0.12 |
| Liver disease | 3 (9.4) | 6 (18.2) | 0.475 |
| Kidney disease | 0 (0) | 0 (0) | 0.317 |
| Heart disease | 3 (9.4) | 0 (0) | 0.114 |
| Pulmonary disease | 4 (12.5) | 3 (9.1) | 0.708 |
| Use of other RA medications | |||
| Methotrexate | 23 (71.9) | 18 (54.5) | 0.2 |
| Hydroxychloroquine | 26 (81.3) | 18 (54.5) | 0.053 |
| Leflunomide | 9 (28.1) | 6 (18.2) | 0.389 |
| Ciclosporin | 3 (9.4) | 6 (18.2) | 0.475 |
| Sulfasalazine | 2 (6.3) | 0 (0) | 0.238 |
| Glucocorticoid use | 18 (56.3) | 24 (72.7) | 0.2 |
DAS28, Disease Activity Score in 28 joints; RA, rheumatoid arthritis.